BCL2 and ovarian carcinoma: When using miRNA inhibitors to suppress endogenous expression of let-7a and miR-34b, the combination of estrogen and progesterone did not change the protein level of Bcl-2 in ovarian cancer cells, suggesting that microRNA let-7a and miR-34b play key roles in the clinical treatment of ovarian cancer using estrogen and progesterone replacement therapy.